LAUSR

Simple Summary Patients with corticotroph pituitary tumors are basically treated with surgery, however, a relatively high rate of patients experience tumor recurrence. There are no clear standards of pharmacological adjuvant treatment of recurrent corticotroph tumors. Few approaches are considered including the strategy of targeting the regulation of cell cycle progression with inhibitors of cyclin-dependent kinases. Approximately 40% of patients have mutations in USP8 or USP48 genes that have a strong effect on tumor biology, including changes in the expression of cell cycle-related genes. Our goal was to assess whether deubiquitinase gene mutations could possibly serve as an indicator for treatment with inhibitors of the cell cycle. It could potentially allow for more rational and personalized treatment of the patients. Abstract Protein deubiquitinases USP8 and USP48 are known driver genes in corticotroph pituitary neuroendocrine tumors (PitNETs). USP8 mutations have pleiotropic effects that include notable changes in genes’ expression. Genes involved in cell cycle regulation were found differentially expressed in mutated and wild-type tumors. This study aimed to verify difference in the expression level of selected cell cycle-related genes and investigate their potential role in response to cell cycle inhibitors. Analysis of 70 corticotroph PitNETs showed that USP8-mutated tumors have lower CDKN1B, CDK6, CCND2 and higher CDC25A expression. USP48-mutated tumors have lower CDKN1B and CCND1 expression. A lower p27 protein level in mutated than in wild-type tumors was confirmed that may potentially influence the response to small molecule inhibitors targeting the cell cycle. We looked for the role of USP8 mutations or a changed p27 level in the response to palbociclib, flavopiridol and roscovitine in vitro using murine corticotroph AtT-20/D16v-F2 cells. The cells were sensitive to each agent and treatment influenced the expression of genes involved in cell cycle regulation. Overexpression of mutated Usp8 in the cells did not affect the expression of p27 nor the response to the inhibitors. Downregulating or upregulating p27 expression in AtT-20/D16v-F2 cells also did not affect treatment response.